Editas Medicine · 1 week ago
Scientist I, Analytical Sciences
Cambridge, MA
Full-time
Onsite
Mid, Senior Level
$115K/yr - $130K/yr
3+ years expEditas Medicine is pioneering the possible in genome editing with a mission to develop transformative genomic medicines. As a Scientist I, you will contribute to the development of CRISPR-based therapeutics and analytical workflows, collaborating with cross-functional teams to meet project goals.
BiotechnologyGeneticsHealth CareMedical
Responsibilities
Design, develop, and execute analytical methods and experiments with a high degree of independence to support process development, investigations, and cross-functional internal stakeholders
Lead LC-MS method development and support the optimization, troubleshooting, and lifecycle management of other release and characterization assays for CRISPR-based therapeutics
Collaborate effectively within a team environment to meet testing turnaround times, project milestones, and quality objectives
Partner with external vendors and contract laboratories to develop, transfer, qualify, and implement phase-appropriate analytical methods
Train and mentor team members as needed
Author, review, and maintain high-quality technical protocols, reports, and electronic laboratory notebook (ELN) documentation
Manage analytical instrumentation, including development of standard operating procedures (SOPs), execution of routine maintenance and repairs, and implementation of preventative maintenance programs
Stay current with scientific literature related to the analytical characterization of CRISPR-based therapeutics, including oligonucleotides, mRNA, and lipid nanoparticles (LNPs)
Qualification
Required
PhD in chemistry, biochemistry, or a related field and a minimum of 3 years of relevant experience in pharmaceuticals or biotechnology, or Master's degree in chemistry, biochemistry, or a related field and 5+ years industry experience
Strong foundation in the chemistry and analytical characterization of oligonucleotides and lipids
Demonstrated expertise in mass spectrometry, including method development and application to the characterization of biological macromolecules
Hands-on experience with spectroscopic and chromatographic techniques
Excellent analytical thinking and problem-solving skills
Demonstrated initiative, creativity, and ability to work efficiently and independently in a laboratory setting
Strong organizational skills with the ability to multitask, prioritize, and adapt in a collaborative team environment
Strong written and verbal communication skills, including the ability to deliver scientific presentations
Preferred
Experience working in GMP-regulated environments
Experience with analytical method validation
Experience managing or working with contract organizations
Familiarity with CRISPR-based gene editing technologies
Benefits
Blue Cross Blue Shield PPO Medical Plan
Company-funded Health Savings Account
Dental and Vision Insurance
Life and Disability Insurance
Dependent Care Account
Tuition Reimbursement
401(k) plan with company match
Employee Stock Purchase Plan
Employee Assistance Plan
Wellness Programs
Flexible Paid Time Off policy
Company
Editas Medicine
Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.
201-500 employees
H1B Sponsorship
Editas Medicine has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (5)
2024 (19)
2023 (5)
2022 (8)
2021 (9)
2020 (16)
Funding
Current Stage
Public CompanyTotal Funding
$931.6MKey Investors
Boris NikolicJuno Therapeutics
2023-06-14Post Ipo Equity· $125M
2021-01-21Post Ipo Equity· $231M
2020-06-23Post Ipo Equity· $215.6M
Leadership Team
Gilmore O'Neill
CEO
Charlene Stern
Executive Vice President & General Counsel
Recent News
2025-11-21
Labiotech UG
2025-11-15
2025-11-11
Company data provided by crunchbase